Merck & Co., Inc. MRK 73.34
Health Care · NYSE · Data as of 2026-08-07
Merck & Co., Inc. (MRK) has delivered +6.8% annualized revenue growth, +9.7% earnings growth, and +6.0% dividend growth over 10 years of data. Ranked #197 of 1968 stocks overall and #19 of 260 in the Health Care sector by Steady Score.
About Merck & Co., Inc.
Company Overview
Merck develops and sells prescription medicines, vaccines and animal-health products. Its human-health portfolio includes cancer treatments, vaccines, hospital medicines and therapies for infectious, cardiovascular and other diseases. Physicians, hospitals, pharmacies, governments and health systems purchase or reimburse these products. Merck Animal Health supplies vaccines, medicines and identification technology for livestock and companion animals worldwide.
Read more
Business Model & Revenue
Revenue comes from patented medicines and vaccines sold through wholesalers, healthcare providers and government programs, plus animal-health products sold through veterinary and producer channels. Product demand depends on diagnoses, treatment guidelines, vaccination programs and reimbursement. Patents provide time-limited exclusivity, so research success, approvals and new indications must offset eventual generic or biosimilar competition. Partnerships and licensing supplement internal development.
Key Facts & Market Position
Oncology drug Keytruda represents a large concentration within Merck's pharmaceutical business, while Gardasil vaccines and animal health provide additional platforms. Clinical trials, regulatory review and manufacturing quality determine whether pipeline assets reach patients. Patent expirations and payer negotiation can change economics quickly, making portfolio renewal and evidence for expanded uses central priorities.